文献速递生殖医学妇科

乳腺癌女性生育力保存:不同卵巢刺激方案的多中心随机对照试验

Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
PubMed 文献 · Hum Reprod · 2022-01-01

这项在荷兰10家医院和比利时1家医院开展的多中心开放标签随机对照优势试验,于2014年1月至2018年12月纳入162名18-43岁选择卵母细胞或胚胎冻存的乳腺癌女性,随机分为他莫昔芬+卵巢刺激组、来曲唑+卵巢刺激组或标准卵巢刺激组。主要结局取卵时获卵丘-卵母细胞复合体(COCs)数三组间无差异。

要点

  • 他莫昔芬或来曲唑联合卵巢刺激方案与标准卵巢刺激相比,取卵时获卵丘-卵母细胞复合体数无差异。
  • 三组冻存卵母细胞或胚胎数亦无差异。
  • 标准卵巢刺激组发生1例严重不良事件:1名女性因卵巢过度刺激综合征住院。

核心结论

  • 在乳腺癌女性中,标准卵巢刺激方案中添加他莫昔芬或来曲唑不影响生育力保存的有效性。

研究设计与样本

  • 多中心、开放标签、随机对照优势试验,在荷兰10家医院和比利时1家医院开展,2014年1月至2018年12月进行。
  • 纳入18-43岁选择卵母细胞或胚胎冻存的乳腺癌女性162名,按1:1:1随机分为他莫昔芬+卵巢刺激组(54名)、来曲唑+卵巢刺激组(53名)和标准卵巢刺激组(55名)。
  • 标准卵巢刺激包括GnRH拮抗剂、重组FSH和GnRH激动剂扳机;随机化采用网络系统,按卵巢刺激开始时口服避孕药使用、雌激素受体(ER)阳性状态和阳性淋巴结分层;患者和照护者未设盲。
  • 主要结局为取卵时获卵丘-卵母细胞复合体(COCs)数;按意向性治疗原则分析。

主要发现

  • 取卵时获卵丘-卵母细胞复合体数均值(±SD):他莫昔芬+卵巢刺激组12.5(10.4),来曲唑+卵巢刺激组14.2(9.4),标准卵巢刺激组13.6(11.6)。
  • 他莫昔芬+卵巢刺激组 versus 标准卵巢刺激组均值差-1.13(95% CI -5.70至3.43);来曲唑+卵巢刺激组 versus 标准卵巢刺激组均值差0.58(95% CI -4.03至5.20)。
  • 调整卵巢刺激开始时口服避孕药使用、ER阳性状态和阳性淋巴结后,他莫昔芬+卵巢刺激组 versus 标准卵巢刺激组均值差-1.11(95% CI -5.58至3.35);来曲唑+卵巢刺激组 versus 标准卵巢刺激组均值差0.30(95% CI -4.19至4.78)。
  • 冻存卵母细胞或胚胎数三组间亦无差异。
  • 标准卵巢刺激组发生1例严重不良事件:1名女性因卵巢过度刺激综合征住院。

局限性

  • 制定假设、把握度分析和样本量计算所依据的现有文献稀少且研究质量低。
  • 本研究把握度不足以按卵泡期、黄体期或随机起始进行亚组分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does ovarian stimulation with the addition of tamoxifen or letrozole affect the number of cumulus-oocyte complexes (COCs) retrieved compared to standard ovarian stimulation in women with breast cancer who undergo fertility preservation? SUMMARY ANSWER: Alternative ovarian stimulation protocols with tamoxifen or letrozole did not affect the number of COCs retrieved at follicle aspiration in women with breast cancer. WHAT IS KNOWN ALREADY: Alternative ovarian stimulation protocols have been introduced for women with breast cancer who opt for fertility preservation by means of banking of oocytes or embryos. How these ovarian stimulation protocols compare to standard ovarian stimulation in terms of COC yield is unknown. STUDY DESIGN, SIZE, DURATION: This multicentre, open-label randomized controlled superiority trial was carried out in 10 hospitals in the Netherlands and 1 hospital in Belgium between January 2014 and December 2018. We randomly assigned women with breast cancer, aged 18-43 years, who opted for banking of oocytes or embryos to one of three study arms; ovarian stimulation plus tamoxifen, ovarian stimulation plus letrozole or standard ovarian stimulation. Standard ovarian stimulation included GnRH antagonist, recombinant FSH and GnRH agonist trigger. Randomization was performed with a web-based system in a 1:1:1 ratio, stratified for oral contraception usage at start of ovarian stimulation, positive estrogen receptor (ER) status and positive lymph nodes. Patients and caregivers were not blinded to the assigned treatment. The primary outcome was number of COCs retrieved at follicle aspiration. PARTICIPANTS/MATERIALS, SETTING, METHODS: During the study period, 162 women were randomly assigned to one of three interventions. Fifty-four underwent ovarian stimulation plus tamoxifen, 53 ovarian stimulation plus letrozole and 55 standard ovarian stimulation. Analysis was according to intention-to-treat principle. MAIN RESULTS AND THE ROLE OF CHANCE: No differences among groups were observed in the mean (±SD) number of COCs retrieved: 12.5 (10.4) after ovarian stimulation plus tamoxifen, 14.2 (9.4) after ovarian stimulation plus letrozole and 13.6 (11.6) after standard ovarian stimulation (mean difference -1.13, 95% CI -5.70 to 3.43 for tamoxifen versus standard ovarian stimulation and 0.58, 95% CI -4.03 to 5.20 for letrozole versus standard ovarian stimulation). After adjusting for oral contraception usage at the start of ovarian stimulation, positive ER status and positive lymph nodes, the mean difference was -1.11 (95% CI -5.58 to 3.35) after ovarian stimulation plus tamoxifen versus standard ovarian stimulation and 0.30 (95% CI -4.19 to 4.78) after ovarian stimulation plus letrozole versus standard ovarian stimulation. There were also no differences in the number of oocytes or embryos banked. There was one serious adverse event after standard ovarian stimulation: one woman was admitted to the hospital because of ovarian hyperstimulation syndrome. LIMITATIONS, REASONS FOR CAUTION: The available literature on which we based our hypothesis, power analysis and sample size calculation was scarce and studies were of low quality. Our study did not have sufficient power to perform subgroup analysis on follicular, luteal or random start of ovarian stimulation. WIDER IMPLICATIONS OF THE FINDINGS: Our study showed that adding tamoxifen or letrozole to a standard ovarian stimulation protocol in women with breast cancer does not impact the effectiveness of fertility preservation and paves the way for high-quality long-term follow-up on breast cancer treatment outcomes and women's future pregnancy outcomes. Our study also highlights the need for high-quality studies for all women opting for fertility preservation, as alternative ovarian stimulation protocols have been introduced to clinical practice without proper evidence. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by a grant (2011.WO23.C129) of 'Stichting Pink Ribbon', a breast cancer fundraising charity organization in the Netherlands. M.G., C.B.L. and R.S. declared that the Center for Reproductive Medicine, Amsterdam UMC (location VUMC) has received unconditional research and educational grants from Guerbet, Merck and Ferring, not related to the presented work. C.B.L. declared a speakers fee for Inmed and Yingming. S.C.L. reports grants and non-financial support from Agendia, grants, non-financial support and other from AstraZeneca, grants from Eurocept-pharmaceuticals, grants and non-financial support from Genentech/Roche and Novartis, grants from Pfizer, grants and non-financial support from Tesaro and Immunomedics, other from Cergentis, IBM, Bayer, and Daiichi-Sankyo, outside the submitted work; In addition, S.C.L. has a patent UN23A01/P-EP pending that is unrelated to the present work. J.M.J.S. reported payments and travel grants from Merck and Ferring. C.C.M.B. reports her role as unpaid president of the National guideline committee on Fertility Preservation in women with cancer. K.F. received unrestricted grants from Merck Serono, Good Life and Ferring not related to present work. K.F. declared paid lectures for Ferring. D.S. declared former employment from Merck Sharp & Dohme (MSD). K.F. declared paid lectures for Ferring. D.S. reports grants from MSD, Gedeon Richter and Ferring paid to his institution; consulting fee payments from MSD and Merck Serono paid to his institution; speaker honoraria from MSD, Gedeon Richter, Ferring Pharmaceuticals and Merck Serono paid to his institution. D.S. has also received travel and meeting support from MSD, Gedeon Richter, Ferring Pharmaceuticals and Merck Serono. No payments are related to present work. TRIAL REGISTRATION NUMBER: NTR4108. TRIAL REGISTRATION DATE: 6 August 2013. DATE OF FIRST PATIENT’S ENROLMENT: 30 January 2014.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Balkenende EME, Dahhan T, Beerendonk CCM, et al. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols. Hum Reprod. 2022. PMID: 35776109. doi:10.1093/humrep/deac145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。